Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
Completed
- Conditions
- Bone Marrow / Autologous Transplants
- Registration Number
- NCT01738373
- Lead Sponsor
- Genzyme, a Sanofi Company
- Brief Summary
The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 262
Inclusion Criteria
- Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012
- Patients who have been informed and who have given their written consent for the access to their medical file
Exclusion Criteria
- Patients already included in a Plerixafor ongoing clinical trial.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of treatment 13 months Associated treatments 13 months The characteristics of the patients who received treatment 13 months Dosage of treatment 13 months Number of CD34+ cells collected following treatment 13 months Number of patients with the existence of one or more predictive factors of poor mobilisation 13 months
- Secondary Outcome Measures
Name Time Method